Hartford A, Fostvedt L, Waterhouse T, Goteti K, Kulkarni H, Lystig T, Millen B, Tannenbaum S, Vaddady P. Connecting ISoP with Statisticians: An Introduction to the Biopharmaceutical Section of the American Statistical Association. American Conference on Pharmacometrics ACoP14, Nov 2023.
Bhattacharya S, Tannenbaum S, Nielsen J, Siripuram V. Advancing quality control (QC) process in pharmacometrics using GIT. American Conference on Pharmacometrics ACoP14, Nov 2023.
Heo N, Nielsen J, Tannenbaum S. Strategies for the Selection of Informed PK Sampling Timepoints in Late Phase Trials. American Conference on Pharmacometrics ACoP12, Nov 2022.
Desai A, Kovanda L, Lademacher C, Tannenbaum S. Dose Prediction and Confirmation using Population Pharmacokinetics and Physiologically Based Pharmacokinetics in Pediatric Patients for Isavuconazole. Accepted to (cancelled) WCoP Apr 2020
Braakman S, Paxson R, Tannenbaum S, Gulati A. Visualizing Parameter Source Reliability and Sensitivity for QSP Models.
Accepted to (cancelled) ASCPT Annual Meeting March 2020
ACoP10 Oct 2019
Gulati A, Tannenbaum S. Using visualization to address the reliability of sources of initial parameter values in a Quantitative Systems Pharmacology (QSP) model.
ACoP9 Oct 2018
AAPS PharmSci 360, Nov 2018
Bosman B, Tannenbaum S, Winklewski P, Den Adel M, Newgreen D, Baka-Ostrowska M. A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO). International Continence Society Annual Meeting Aug 2013
Ait-Oudhia S, Tannenbaum S, Lowe PJ, and Mager DE. Population Pharmacokinetic Model of Canakinumab in Patients with Active Rheumatoid Arthritis. AAPS National Biotechnology Conference May 2011
Ait-Oudhia S, Lowe PJ, Tannenbaum S, and Mager DE. Bridging Clinical Outcomes to Canakinumab in Rheumatoid Arthritis Patients to a Population PK/PD Model Using IL-1β Kinetics. AAPS Annual Meeting, Oct 2011
Roberts J, Sunkara G, Tannenbaum S, Vahn L, Chakraborty A. Ethnic Sensitivity Assessment of Canakinumab Pharmacokinetics and Pharmacodynamics in Gouty Arthritis Patients. ASCPT Annual Meeting March 2012
Tannenbaum S, Chakraborty A, Vaidya S, Heep M, Chaves R, Benzinger D. Pharmacokinetic Considerations for Use of Daptomycin in Patients with Renal Impairment. 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Sept 2010
Lowe PJ, Tannenbaum S, Gautier A, Massanari M. Omalizumab may normalize IgE production rate in patients with moderate-to-severe atopic asthma. American College of Clinical Pharmacy Annual Meeting Oct 2010
Tannenbaum S, Chakraborty A, Rordorf C, Lowe P. A Methodology for Model-Based Bioequivalence of Two Manufacturing Variants of a Monoclonal Antibody. ACoP2 Oct 2009
Pinault G, Pillai G, Steimer J-L, McDevitt H, Tannenbaum S, Buchheit V. Sharing experiences of a dedicated SAS programming group in a M&S department. ACoP2, Oct 2009
Tannenbaum S, Chakraborty A, Rordorf C, Gautier A, Lowe P. Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndrome and systemic juvenile idiopathic arthritis. AAPS Annual Meeting Nov 2008
Tannenbaum S, Gautier A, Lowe P. A Mechanism Based Binding Model for the Population Pharmacokinetics and Pharmacodynamics of ACZ885, a Monoclonal Antibody in Development for Rheumatoid Arthritis. AAPS Annual Meeting Nov 2008
Stoellner D, Tannenbaum S, Gautier A, Deckert F, Lowe P. On the use of a captured target biomarker to deduce the extent of binding of canakinumab to IL-1β in patients with Muckle-Wells Syndrome and rheumatoid arthritis. Monoclonal Antibodies: Cutting-edge Science for New Medicines workship. EUFEPS June 2008
Lowe P, Tannenbaum S, Gautier A, Jiminez P, Panalhoo Z. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.
European Respiratory Society Sept 2007
European Academy of Allergology and Clinical Immunology, June 2008
Tannenbaum S, Lee P, Sun H, Williams G, Lesko L, Temple R. A Comparison of Clinical Study Designs using Fixed Dosing (FD) versus Covariate Adjusted Dosing (CAD). AAPS Annual Meeting Oct 2003
Tannenbaum S, Holford N, Mould D, Lee H, Peck C. Validation of a Novel Method of Combining Both Continuous and Categorical Covariates in a Single Joint Function for Clinical Trial Simulation. ASCPT Annual Meeting Apr 2003
Lee H, Tannenbaum S, Peck C. A Novel Method For Deriving Intersubject Variability For Baseline Hazard Rates and Relative Risks For Secondary Vascular Events, ASCPT Annual Meeting Apr 2003
Tannenbaum S, Kim S, Mayersohn M. Estimation of the Fractional Conversion of Cocaine to Cocaethylene When Co- Administered With Ethanol. ASCPT Annual Meeting March 2002
Tannenbaum S and Mayersohn M. Drugs that Undergo Saturable Elimination Can Be Allometrically Scaled: Ethanol as a Prototype Drug. AAPS Annual Meeting Oct 2001
Tannenbaum S and Mayersohn M. A Pharmacokinetic/Pharmacodynamic Analysis of Cocaine (C), Cocaethylene (CE), and Cocaine Plus Ethanol (C+E) in the Dog: A Literature Evaluation. Building Competitive Research Careers: A Symposium for the Arizona Biomedical Research Community, Sept 1999
Tannenbaum S and Mayersohn M. A Pharmacokinetic/Pharmacodynamic Analysis of Cocaine (C), Cocaethylene (CE), and Cocaine Plus Ethanol (C+E) in the Dog: A Literature Evaluation. AAPS Annual Meeting Nov. 1999
Tannenbaum S and Mayersohn M. A Mathematical Approach to Predicting the Approximate Dose and Time of Dosing in Humans. AAPS Annual Meeting Nov 1998
Tannenbaum S and Mayersohn M. A Mathematical Approach to Predicting the Approximate Dose and Time of Dosing in Humans. The Flinn Foundation Fourth Annual Biomedical Symposium. December 1998
Tannenbaum S, Boxenbaum H, Mayersohn M. Allometric Analysis of Organ Extraction Ratios. AAPS Annual Meeting Nov 1997
Tannenbaum S and Mayersohn M. Prediction of Pharmacokinetic Parameters in Humans on the Basis of Allometric Scaling using a ‘Global’ Slope. AAPS Annual Meeting Oct 1996.
Tannenbaum S, Sinha V, Mayersohn M. Potential Errors in the Use of Body Burden Calculations for Estimation of Toxicokinetic Parameters. Society of Toxicology Annual Meeting March 1996